Currently finishing a 12 week cycle of IPA and CJC.

The 12-week combination finished — now the question is whether to extend, switch, restart after a break, or stop. The answer depends on your goals, which tier of evidence you're comfortable operating from, and whether you saw measurable changes during those 12 weeks.

Most People Cycle Off for 4-8 Weeks Before Restarting

This is the default strategy in research communities because pulsatile secretagogues like Ipamorelin and CJC-1295 DAC (or Mod GRF 1-29, depending on which version you used) can theoretically lead to receptor desensitization if used continuously for extended periods. The confidence level here: low to moderate. No controlled human trial has tested continuous secretagogue use beyond 12 weeks versus cycled use head-to-head. The logic is borrowed from GH therapy protocols where pulsatility is thought to preserve sensitivity, but direct human data confirming optimal cycling intervals for these peptides doesn't exist.

The washout period gives the growth hormone secretagogue receptor 1a (GHS-R1a) time to normalize. If you saw good results in weeks 1-8 but noticed diminishing returns in weeks 10-12 — less noticeable recovery, less body composition shift, or reduced sleep quality — that's a practical signal that desensitization may be starting. If results stayed consistent through week 12, you might have more runway. Some researchers extend to 16 weeks before cycling off, but past that point you're operating without even observational precedent.

The Mechanistic Reason Is Receptor Downregulation, Not Exhausted Pituitary Capacity

Ipamorelin binds the GHS-R1a receptor on somatotroph cells in the anterior pituitary, activating Gq signaling and triggering intracellular calcium release, which leads to growth hormone secretion. CJC-1295 DAC (if that's what you used) is a long-acting GHRH analog that binds the GHRH receptor (GHRHR), activating adenylyl cyclase via Gs signaling and raising cAMP, which also triggers GH pulses. If you used Mod GRF 1-29 instead, it does the same thing but clears much faster — half-life around 30 minutes instead of 6-8 days.

Chronic agonism at GHS-R1a can lead to receptor internalization and reduced surface expression. This has been demonstrated in vitro with ghrelin and synthetic GHS compounds. The pituitary doesn't "run out" of growth hormone — stores regenerate quickly — but the receptors that trigger release can become less responsive. GHRHR shows similar internalization after prolonged stimulation in cell culture models, though human in vivo data are sparse.

The stacking logic behind Ipamorelin and CJC (or Mod GRF) is synergy: one compound works on GHS-R1a, the other on GHRHR, and together they amplify the growth hormone pulse more than either compound alone. This synergy has been shown in rodent models where dual-pathway stimulation produced greater IGF-1 elevation than single agents. No large controlled human trial has published this comparison for these specific peptides, but the mechanism is well-accepted based on receptor biology. For research purposes only, most people dose ipamorelin at 200-300 mcg per injection, 2-3 times daily, and pair it with 100 mcg of Mod GRF 1-29 (or rely on CJC-1295 DAC's sustained activity with less frequent injections).

What the Evidence Shows: Mostly Rodent Data, Some Uncontrolled Human Observations

In vitro and rodent models: Ipamorelin consistently raises growth hormone in Sprague-Dawley rats at doses of 2-20 nmol/kg, with peak GH levels 15-30 minutes post-injection. Unlike earlier secretagogues like GHRP-6 or hexarelin, ipamorelin does not elevate cortisol, prolactin, or ACTH at growth-hormone-releasing doses. CJC-1295 DAC showed sustained GH and IGF-1 elevation for up to two weeks in healthy adult men in a single-dose Phase I trial (Teichman et al., 2006). That study was dose-ranging and safety-focused — it was not designed to measure long-term efficacy or cycling outcomes.

Unpublished human experience: Online research communities report body composition changes (lean mass gain, modest fat loss) and improved recovery during 8-12 week cycles of the ipamorelin + CJC stack. The most commonly reported subjective benefits are better sleep quality and faster recovery from training. None of this has been captured in controlled trials. The observations are real, but the lack of placebo controls means the magnitude of effect could be smaller than reported.

No long-term human RCTs exist for continuous use beyond 12 weeks. The longest-duration controlled trial for a similar compound is with Tesamorelin, a GHRH analog used for HIV-associated lipodystrophy, where 26-week continuous use showed sustained visceral fat reduction without apparent desensitization. Tesamorelin is structurally different from CJC and approved under medical supervision, so the comparison is indirect.

What the Data Doesn't Tell Us and Why It Matters

We don't have direct evidence for optimal cycle length. The 12-week cutoff is tradition borrowed from anabolic steroid cycling and applied to peptides without rigorous testing. It's plausible but not proven.

We don't know if desensitization happens uniformly across individuals. Some users report diminishing returns by week 10; others run 16-week cycles with consistent results. Genetic variation in GHS-R1a expression or GHRHR density could explain this, but no studies have profiled responders versus non-responders.

We don't know if a 4-week break is enough, or if 8 weeks is overkill. Receptor resensitization timelines in humans for GHS-R1a are not published. Cell culture models suggest receptor recovery within 48-72 hours after agonist withdrawal, but whole-organism dynamics involve more than surface receptor count — downstream signaling adaptations, feedback from IGF-1, and somatostatin tone all matter.

We don't know if stacking long-acting CJC-1295 DAC with pulsatile ipamorelin creates different desensitization kinetics than using Mod GRF 1-29 (the short-acting version). DAC keeps GHRHR stimulated for days; Mod GRF clears in under an hour. The former might risk more receptor adaptation, but no head-to-head comparison exists.

Finally, we don't know if cycling off entirely is better than switching to a lower maintenance dose. Some researchers drop to 2-3 injections per week instead of daily during "cruise" phases. This mirrors TRT logic but hasn't been tested for secretagogues.

FAQ

Q: Should I run another 12 weeks immediately or take a break?

Take a break. The mechanistic case for receptor recovery is stronger than the case for back-to-back cycles. Four weeks off is the minimum most researchers use; eight weeks is more conservative. If you saw steady progress through week 12, you could consider a shorter break. If results tapered off, take the full eight.

Q: Can I switch to a different growth hormone secretagogue instead of cycling off completely?

Yes, but the rationale is weak. Switching from ipamorelin to GHRP-2 or hexarelin still hits GHS-R1a — you're not giving that receptor a rest. Switching from CJC to sermorelin or tesamorelin still hits GHRHR. The only real alternative is switching to MK-677, an oral GHS-R1a agonist with a longer half-life, but that's continuous stimulation, not pulsatile, and it carries its own desensitization risk.

Q: What blood markers should I check before restarting?

IGF-1 is the most useful marker. If your IGF-1 is still elevated weeks after stopping, your endogenous GH axis might still be suppressed. Fasting glucose and HbA1c matter if you're concerned about insulin sensitivity — chronic GH elevation can impair glucose tolerance. Prolactin and cortisol are worth checking if you used GHRP-6 or hexarelin (which raise them), but ipamorelin is selective enough that this is less of a concern.

Q: Is there any reason to stay on continuously instead of cycling?

Only if you're willing to accept the unknown risk. Tesamorelin is dosed daily for 26+ weeks in clinical settings without reported desensitization, but that's under medical monitoring for a specific indication. Some researchers argue that true desensitization is overstated and that consistent dosing maintains stable IGF-1 elevation better than cycling. The evidence doesn't support that claim strongly enough to recommend it as default practice.

Q: What happens if I just stop cold without a PCT or taper?

Nothing dramatic. These are secretagogues, not exogenous hormones. Your natural GH pulsatility should resume within days to weeks. You might notice a temporary dip in recovery or sleep quality as your body recalibrates, but this isn't the same as coming off testosterone or thyroid hormone. No formal post-cycle therapy is required.

---

This content is for informational and research purposes only. Ipamorelin and CJC-1295 are not approved for human use outside of clinical trials. Consult a licensed medical professional before starting, stopping, or modifying any research protocol.